impact factor
logo
 

Case Reports

 

Effects of tumor necrosis factor-α inhibitors in mothers and daughters concordant for HLA-B27-positive ankylosing spondylitis


1, 2, 3, 4, 5, 6, 7, 8, 9, 10

 

  1. Research Center of Systemic Autoinflammatory Diseases and Behçet’s disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena; and Rheumatology Unit, Department of Clinical Medicine, DIMED, University of Padua, Italy.
  2. Rheumatology Unit, Department of Clinical Medicine, DIMED, University of Padua; and Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  3. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  4. Institute of Paediatrics, Policlinico A. Gemelli, Università Cattolica Sacro Cuore, Rome, Italy.
  5. Division of Rheumatology, Allergy, and Clinical Immunology, University of California, Davis, USA; and Division of Rheumatology and Clinical Immunology, Humanitas Research Hospital, Rozzano, Milan, Italy.
  6. Research Center of Systemic Autoinflammatory Diseases and Behçet’s disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
  7. Rheumatology Unit, Department of Clinical Medicine and Surgery, University Federico II, Naples, Italy.
  8. Research Center of Systemic Autoinflammatory Diseases and Behçet’s disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
  9. Research Center of Systemic Autoinflammatory Diseases and Behçet’s disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.
  10. Research Center of Systemic Autoinflammatory Diseases and Behçet’s disease Clinic, Department of Medical Sciences, Surgery and Neurosciences, University of Siena, Siena, Italy.

CER8122
2015 Vol.33, N°3
PI 0411, PF 0413
Case Reports

Free to view
(click on article PDF icon to read the article)

PMID: 25962691 [PubMed]

Received: 15/11/2014
Accepted : 06/02/2015
In Press: 11/05/2015
Published: 22/06/2015

Abstract

OBJECTIVES:
Pharmacogenomics is considered as the new frontier to predict the response to treatments and it can also be based on the comparison of family members being treated for the same condition. No data are available on the impact of anti-tumour necrosis factor (TNF)-α therapies in members of the same family with ankylosing spondylitis (AS).
METHODS:
We describe three mother-daughter couples concordant for AS and HLA-B27, both treated with TNF-α inhibitors, for whom the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), and Ankylosing Spondylitis Disease Activity Score (ASDAS)-CRP were evaluated during a follow-up of 24 months.
RESULTS:
All patients manifested improvements of all scores, but the daughters had a more prominent effect achieving faster complete disease remission.
CONCLUSIONS:
We hypothesise that longer standing chronic inflammation and older age may cause a less prompt and effective response to treatment in SA when compared with their genetically related controls.

Rheumatology Article